{"version":"1.0","type":"link","title":"First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up.","author_name":"Ogata T 외","author_url":"https://prs-insight.online/author/Ogata%20T","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167198","thumbnail_width":1200,"thumbnail_height":630}